If there is a deal with gsk or another BP that includes a buyout (I prefer partnership), I would expect to see a large gap between their offer price and what we're willing to sell for. We know what LL is worth, but any potential buyer would have to sell the high sp to their BoD and shareholders. Rather than offer us 20-50 times our current share price (which still wouldn't be enough in my opinion), I would expect it would be more palatable to their shareholders to include milestone payments based on LL's performance in future trials. Therefore, they can drop a sizeable yet smaller amount of change up front, and then easily justify the milestone payments based on performance and future revenue opportunities. The trick would be to not stretch the milestone payments too far out so that it's also acceptable to the CYDY BoD and shareholders.

Quote:

---

not sure how gsk stands at this time but toward end of june beginning july they were holding 305 million gsk shares in their treasury with a value of $14.2 -$14.4 billion.in a recent filing their r and d money runs about $7 billion.

---